Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia

Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease
Chen-Hsiang LeeJien-Wei Liu

Abstract

Meropenem (MEM; 2 g/8 hr; minimum inhibitory concentration [MIC] = 256 mg/L) plus sulbactam (SUL; 1 g/8 hr; MIC = 128 mg/L) (two-drug-therapy period), and subsequent additional intravenous colistin (COL; 2.5 mg/kg/12 hr) and intraventricular (COL, 5 mg/day; MIC = 1 mg/L) (three-drug-therapy period) were sequentially used in a patient with postneurosurgery bacteremic meningitis due to a multidrug-resistant Acinetobacter baumannii (MDRAB) isolate (AB(1)). We detected 4- to 32-fold increases in peak or trough cerebrospinal fluid bactericidal titer and serum bactericidal titer in three-drug-therapy period when comparing to those in two-drug-therapy period. The time-kill study with MEM, SUL, and COL alone or varied combinations (all at 1 x MIC) against AB(1) and another genetically nonrelated MDRAB isolate (AB(134) [MICs of MEM = 64 mg/L, SUL = 16 mg/L, and COL = 1 mg/L]) was performed. The two-drug combinations (MEM + SUL, MEM + COL, and SUL + COL) each elicited different inhibitory effect on AB(1) and AB(134) at 6 hr. Bacterial regrowth at 24 hr was observed in the experiments in which the MDRAB isolate was inhibited earlier by COL alone (AB(1) and AB(134)), by MEM plus SUL (AB(1)), and by MEM plus COL (AB(134)), but not in SUL pl...Continue Reading

References

Dec 19, 2002·The Pediatric Infectious Disease Journal·Yhu-Chering HuangTzou-Yien Lin
Jan 20, 2004·The Journal of Antimicrobial Chemotherapy·Wen-Chien KoYin-Ching Chuang
Dec 21, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J Y ChoiJ M Kim
Aug 26, 2006·The Lancet Infectious Diseases·Jian LiDavid L Paterson
Feb 10, 2007·The Journal of Antimicrobial Chemotherapy·Roxanne J OwenDenis Spelman

❮ Previous
Next ❯

Citations

Apr 5, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Y-T LeeP-R Hsueh
Sep 18, 2013·International Journal of Antimicrobial Agents·Syamhanin AdnanJason A Roberts
Mar 24, 2012·The Journal of Antimicrobial Chemotherapy·Yun CaiNan Bai
Sep 1, 2012·The Pediatric Infectious Disease Journal·Pranita D TammaAdam L Hersh
Jan 12, 2011·The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases·Felipe Francisco TuonLuis A Borba
Nov 7, 2009·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Antonio CascioAntonio David
Dec 4, 2014·International Journal of Antimicrobial Agents·Wentao NiYouning Liu
Jun 20, 2017·Natural Product Reports·Francesc Rabanal, Yolanda Cajal
Mar 30, 2017·Frontiers in Cellular and Infection Microbiology·Chang-Ro LeeSang Hee Lee
Nov 5, 2020·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Keisuke KagamiYoh Takekuma
Feb 7, 2018·Indian Journal of Medical Microbiology·Shakti LaishramBalaji Veeraraghavan
May 11, 2018·Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine·Pradeepkumar HiremathKarthik Rao
Apr 23, 2021·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Sazlyna Mohd Sazlly LimFekade B Sime

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Bacterial Meningitis

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

Bacterial Meningitis (ASM)

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.